Literature DB >> 24176449

Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.

Francesco Liistro1, Italo Porto, Paolo Angioli, Simone Grotti, Kenneth Ducci, Giovanni Falsini, Leonardo Bolognese.   

Abstract

BACKGROUND: Paclitaxel-eluting balloons (PEBs) are a promising alternative to drug-eluting stent (DES) in the treatment of coronary stenoses. The aim of our study was to compare the 9-month restenosis rates of a strategy of predilatation with PEB followed by bare-metal CoCr stent (PEB + BMS group) versus implantation of everolimus DES (DES group).
METHODS: This randomized, single-center study planned to enroll 366 patients with stable angina (183 patients per arm) undergoing percutaneous coronary intervention of a de novo, native coronary artery stenosis ≤ 15 mm in length. Primary end point, in a noninferiority study design, was 9-month binary angiographic restenosis. A frequency-domain optical coherence tomography substudy investigated the percentage of uncovered stent struts per lesion, the percentage of malapposed/uncovered struts per lesion, and the percentage of net volume obstruction at 9-month follow-up among the first consecutive 30 patients enrolled in the PEB + BMS group.
RESULTS: The study was prematurely halted after enrollment of 125 patients, 59 in the PEB + BMS group and 66 in the DES group, because of excess of ischemia-driven target lesion revascularization in the PEB + BMS group. When all the enrolled patients completed their follow-up, IDLTR rates were 14% in the PEB + BMS versus 2% in DES group (P = .001). Binary restenosis, either in-stent or in-segment, was significantly higher in the PEB + BMS compared with DES group (17% vs 3% [P = .01] and 25% vs 4% [P = .009] respectively). Frequency-domain optical coherence tomography demonstrated important neointimal regrowth in the PEB + BMS group, similar to historical BMS data.
CONCLUSION: In the treatment of de novo coronary stenosis, a strategy of predilatation with PEB before BMS implantation was significantly inferior to implantation of an everolimus DES stent in terms of 9-month target lesion revascularization. Frequency-domain optical coherence tomography data confirm the lack of efficacy of this strategy.
© 2013.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24176449     DOI: 10.1016/j.ahj.2013.08.023

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Impact of drug-eluting balloon (pre- or post-) dilation on neointima formation in de novo lesions treated by bare-metal stent: the IN-PACT CORO trial.

Authors:  Francesco Burzotta; Marta Francesca Brancati; Carlo Trani; Giancarlo Pirozzolo; Gianluigi De Maria; Antonio Maria Leone; Giampaolo Niccoli; Italo Porto; Francesco Prati; Filippo Crea
Journal:  Heart Vessels       Date:  2015-04-12       Impact factor: 2.037

Review 2.  Basic Concepts and Clinical Outcomes of Drug-Eluting Balloons for Treatment of Coronary Artery Disease: An Overview.

Authors:  C D Ramakrishna; Bhargav A Dave; Pankaj S Kothavade; Kajal J Joshi; Ashok S Thakkar
Journal:  J Clin Diagn Res       Date:  2017-06-01

3.  Drug-eluting balloons with provisional bail-out or adjunctive stenting in de novo coronary artery lesions-a systematic review and meta-analysis.

Authors:  Smit Patel; Tatiana Svermova; Anne Burke-Gaffney; Richard G Bogle
Journal:  Cardiovasc Diagn Ther       Date:  2018-04

Review 4.  Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials.

Authors:  Kongyong Cui; Shuzheng Lyu; Xiantao Song; Fei Yuan; Feng Xu; Min Zhang; Wei Wang; Dongfeng Zhang; Jing Dai
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240

Review 5.  Drug-coated balloon in combination with bare metal stent strategy for de novo coronary artery disease: A PRISMA-compliant meta-analysis of randomized clinical trials.

Authors:  Wenjie Lu; Yongjian Zhu; Zhanying Han; Xi Wang; Xule Wang; Chunguang Qiu
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 6.  Comparison of drug-eluting balloon versus drug-eluting stent for treatment of coronary artery disease: a meta-analysis of randomized controlled trials.

Authors:  Lulu Liu; Bin Liu; Jiajun Ren; Gang Hui; Chao Qi; Junnan Wang
Journal:  BMC Cardiovasc Disord       Date:  2018-03-02       Impact factor: 2.298

7.  Relationship between Metabolic Syndrome and Clinical Outcome in Patients Treated with Drug-Eluting Stenting after Rotational Atherectomy for Complex Calcified Coronary Lesions.

Authors:  Bin Hu; Changbo Xiao; Zhijian Wang; Dean Jia; Shiwei Yang; Shuo Jia; Guangyao Zhai; Hongya Han; Xiaohan Xu; Dongmei Shi; Yujie Zhou
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

Review 8.  Drug-Eluting Balloons in the Treatment of Coronary De Novo Lesions: A Comprehensive Review.

Authors:  Rasmus Kapalu Broge Richelsen; Thure Filskov Overvad; Svend Eggert Jensen
Journal:  Cardiol Ther       Date:  2016-07-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.